Genpact secondary risk is minimal, says RW Baird Baird expects shares of Genpact to be weak following its announcement of a secondary offering. The firm believes the ongoing secondary risk is minimal and views the company risk/reward as favorable citing its strong management team, execution, and potential upside to Q4 estimates. Shares are Outperform rated with a $20 price target.
News For G From The Last 14 Days
Check below for free stories on G the last two weeks.